People

Christopher D. Barnstable-Brown

Counsel

Barnstable-Brown_Chris

Chris Barnstable-Brown's practice focuses on mergers and acquisitions, corporate governance and corporate finance transactions. He has extensive experience advising public and private companies and private equity sponsors in a wide variety of complex corporate matters, including domestic and international mergers and acquisitions, strategic investments, joint ventures, asset sales, and matters related to hedge fund activism. He also has experience advising issuers, borrowers, underwriters, administrative agents, and lenders in domestic and international financing transactions, including public and private offerings of debt and equity securities and syndicated lending transactions. Mr. Barnstable-Brown also advises emerging growth companies throughout their lifecycles, including with respect to corporate organization and governance matters, venture and mezzanine financings and sales transactions.

Mr. Barnstable-Brown was born in Louisville, Kentucky. Prior to joining WilmerHale in 2014, Mr. Barnstable-Brown was an associate at Cravath, Swaine & Moore LLP. Previously, he was a judicial law clerk for the Honorable Boyce F. Martin, Jr. of the US Court of Appeals for the Sixth Circuit.

Mr. Barnstable-Brown was named a 2015, 2016 and 2017 "Rising Star" by New York Super Lawyers.

Recent Highlights

Mr. Barnstable-Brown’s recent transactions include representing:

  • The underwriters in connection with the initial public offering of MaxPoint Interactive, Inc.
  • Bellerophon Therapeutics, Inc., in connection with its initial public offering 
  • Durata Therapeutics, Inc., a NASDAQ-listed pharmaceutical company, in connection with its sale to Actavis plc for $675 million in cash plus contingent value rights representing potential cash payments of up to an additional $155 million 
  • Intercept Pharmaceuticals, Inc. in connection with public offerings of over $825 million of its common stock
  • Federal Agricultural Mortgage Corporation (Farmer Mac) in connection with public offerings of $150 million of its preferred stock
  • PAE, a portfolio company of private equity firm Lindsay Goldberg, in its acquisition of the Applied Technology Division of Computer Sciences Corporation
  • Archer Daniels Midland Company in connection with its recommended $3.5 billion offer to acquire GrainCorp Ltd. of Australia, which followed ADM taking a 19.8% equity stake in GrainCorp
  • The initial purchasers in connection with the $250 million 144A/Reg S high-yield senior debt offering of Brightstar Corp.
  • The underwriters in connection with the $450 million registered offering of senior notes of Ralcorp Holdings, Inc., the proceeds of which were used to finance the acquisition of American Italian Pasta Company
  • The underwriters in connection with offerings of $5 billion of senior notes of Hewlett-Packard Company, including senior notes issued to finance the acquisition of 3PAR, Inc.
  • JPMorgan Chase Bank N.A., as administrative agent, in connection with the $4 billion credit facility of Hess Corporation
  • Credit Suisse AG, as administrative agent, in connection with credit facilities entered into to finance the acquisition of Taylor Morrison Homes by a consortium of private equity sponsors led by TPG and Oaktree Capital Management
  • The underwriters in connection with a public offering of common stock of Progenics Pharmaceuticals, Inc.

Publications & News

View

November 14, 2017

WilmerHale Reps Apellis Pharmaceuticals in Initial Public Offering

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced the closing of its initial public offering.

August 7, 2017

WilmerHale Reps Tetraphase Pharmaceuticals in $65M Public Offering of Common Stock

Tetraphase Pharmaceuticals, Inc. has closed on an underwritten public offering of 10,000,000 shares of its common stock for a public offering price of $6.50 per share, with gross proceeds of $65 million.

July 5, 2017

WilmerHale Represents Blue Apron Holdings, Inc. in IPO

Blue Apron's mission is to make incredible home cooking accessible to everyone. Launched in 2012, Blue Apron has grown to $795 million in annual revenue to become the leading US meal plan delivery company.

April 26, 2017

WilmerHale Represents Medtronic in Senior Notes Offering

On March 28, 2017, Medtronic plc's wholly owned subsidiaries, Medtronic, Inc. and Medtronic Global Holdings S.C.A., issued an aggregate principal amount of $2 billion of senior notes in concurrent SEC-registered underwritten public offerings.

September 22, 2016

WilmerHale Reps Eleven Biotherapeutics in Acquisition of Viventia Bio

The acquisition creates a NASDAQ-listed company focused on the development of novel therapies based upon antibody fragments genetically fused to cytotoxic proteins, or targeted protein therapeutics, as new treatments in areas of oncology with significant unmet need.

August 17, 2016

WilmerHale Reps Eleven Biotherapeutics in License Agreement with Roche for Antagonist Antibody Technology

WilmerHale represented Eleven Biotherapeutics, a biopharmaceutical company researching and developing protein therapeutics to treat diseases of the eye, in the negotiation of a license agreement with Roche for Eleven's IL-6 antagonist monoclonal antibody program, including its preclinical ophthalmic drug EBI-031.

July 18, 2016

WilmerHale Advises Intercept Pharmaceuticals in $460M Public Offering

Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, has announced the closing of an underwritten public offering of $460 million aggregate principal amount of 3.25% convertible senior notes due 2023.

October 8, 2014

Actavis to Acquire Durata Therapeutics, Inc.

On October 6, 2014, WilmerHale client Durata Therapeutics announced that it had entered into a definitive merger agreement with Actavis plc under which a subsidiary of Actavis will commence a tender offer to acquire all of the outstanding shares of Durata common stock.

Practices

Skip Navigation Links.

Education

JD, magna cum laude, Boston University School of Law, 2008, Editor-in-Chief, Review of Banking and Financial Law

BS, Management, Purdue University, 2005

Bar Admissions

New York

Clerkships

The Hon. Boyce F. Martin, Jr., US Court of Appeals for the Sixth Circuit, 2008 - 2009

Skip Navigation Links.